ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Surgery was scheduled to occur within 6 weeks after the last neoadjuvant treatment; patients could then receive optional adjuvant therapy (up to four cycles of chemotherapy, radiotherapy, or both) per ...

The American University in Cairo's Research and Creativity Convention (RCC) brings together diverse research, design, entrepreneurship, innovation, and creativity projects to display their growth and ...

Robot-assisted partial cystectomy following neoadjuvant chemotherapy in selected patients may be a bladder-preserving option for patients with muscle-invasive bladder cancer. Robot-assisted ...

The use of adjuvant chemotherapy in patients with NSCLC can lead to a modest increase in survival. Platinum-based regimens are the most studied and should be considered the regimens of choice.

Potassium is a mineral needed for vital bodily functions. But people with kidney disease may need to know which high potassium foods to avoid. Here we discuss how to create such a diet. If you ...

Long-term follow-up showed that neoadjuvant pembrolizumab (Keytruda) and chemotherapy followed by surgery and adjuvant pembrolizumab continued to improve event-free (EFS) and overall survival (OS) ...

“Our findings suggest that durvalumab did not improve outcomes compared with cetuximab in patients with HNSCC with contraindications to cisplatin,” the authors concluded. “These findings are ...

Building upon these findings, the phase 3 MATTERHORN trial (NCT04592913) examined neoadjuvant durvalumab (Imfinzi) plus FLOT followed by adjuvant durvalumab plus FLOT and then durvalumab monotherapy.

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Neuroendocrine Carcinoma.